in vitro News and Research

RSS

Researchers establish new method to patch damaged heart with tissue-engineering platform

Researchers at Columbia Engineering have established a new method to patch a damaged heart using a tissue-engineering platform that enables heart tissue to repair itself.

7 May 2011

Six1 transcription factor an essential regulator in development of embryonic lung epithelial stem cells

Scientists at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Six1 transcription factor is an essential regulator in the development of embryonic lung epithelial stem cells.

6 May 2011

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M Integrated Cycler.

From Quest Diagnostics 6 May 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

Techne decides to pay a dividend of $0.27 per share for quarter ended March 31, 2011

Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.27 per share for the quarter ended March 31, 2011.

From BiosPacific, Inc. 3 May 2011

Techne acquires Tocris Holdings

Techne Corporation announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries, a leading supplier of reagents for non-clinical life science research.

3 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

GSN receives NIH grant for non-invasive prenatal test trial in genetic abnormalities

Gene Security Network announced today that they have received a $2 million grant from the National Institutes of Health to conduct a clinical trial applying Parental Support technology for non-invasive prenatal diagnosis.

28 Apr 2011

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market Xpert® Flu. The diagnostic test, which runs on Cepheid's GeneXpert® System, simultaneously detects and differentiates Influenza A, Influenza B, and the 2009 H1N1 influenza virus in about one hour.

26 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

Signaling pathway reveals mechanism for B cell differentiation in immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

25 Apr 2011

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement granting Hanmi Pharmaceuticals exclusive rights to their lead compound, KX01, for all oncology indications in selected Asian Territories.

21 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

RTCA HT instrument from Roche employs high-throughput real-time cell analysis

The new xCELLigence RTCA HT Instrument from Roche (SWX:RO) (SWX:ROG) (Pink Sheets:RHHBY) rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product.

21 Apr 2011

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

Intrinsic Bioprobes Inc. ("IBI") today announced the launch of its first mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI's MASSAY® platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

20 Apr 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Clontech releases iDimerize inducible dimerization systems

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the iDimerize inducible dimerization systems. Based on the widely used ARGENT™ technology developed by ARIAD Pharmaceuticals, Inc., the iDimerize systems enable precise, real-time control of protein-protein interactions using specific cell-permeable chemical ligands, called dimerizers.

20 Apr 2011

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Systagenix announced on 20 April 2011 that a recent product evaluation published in the journal Wounds UK, Vol 7, No 1, demonstrates the clinical effectiveness of ADAPTIC TOUCH® as a primary wound contact layer that addresses the needs of both patients and healthcare professionals.

20 Apr 2011

in vitro News and Research

Researchers establish new method to patch damaged heart with tissue-engineering platform

Six1 transcription factor an essential regulator in development of embryonic lung epithelial stem cells

Quest Diagnostics' Simplexa C. difficile test is now available in Europe

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

ChipDX identifies gene expression signature in early-stage breast tumors

Techne decides to pay a dividend of $0.27 per share for quarter ended March 31, 2011

Techne acquires Tocris Holdings

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

GSN receives NIH grant for non-invasive prenatal test trial in genetic abnormalities

FDA grants Cepheid marketing clearance for Xpert Flu diagnostic test

Researchers discover molecular mechanisms behind autoimmunity

Signaling pathway reveals mechanism for B cell differentiation in immune response

Hanmi granted exclusive rights to Kinex KX01 Src kinase/pretubulin dual mechanism inhibitor for oncology indications

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

RTCA HT instrument from Roche employs high-throughput real-time cell analysis

Intrinsic Bioprobes launches mass spectrometry-based protein assays for in-vitro diagnostic testing

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Clontech releases iDimerize inducible dimerization systems

Study demonstrates clinical effectiveness of Systagenix ADAPTIC TOUCH as a primary wound contact layer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News